AUTHORS
Ning Ma, PhD, Xiangyu Zhao, MD, PhD2, Lan-Ping Xu3, Xiaohui Zhang, MD4, Xiao-Dong Mo, MD5, Yuanyuan Zhang6, Xiaosu Zhao7, Yu Wang8, Yi-Fei Cheng, MD9, Kaiyan Liu10, Xiaojun Huang, MD,PhD11, Ying-Jun Chang12
AFFILIATIONS
1 Peking University People's Hospital, Beijing, Beijing, China
2 Peking University People's Hospital, Beijing, Beijing, China
3 Peking University People's Hospital, Beijing, Beijing, China
4 Peking University People's Hospital, Beijing, Beijing, China
5 Peking University People's Hospital, Beijing, Beijing, China
6 Peking University People's Hospital, Beijing, Beijing, China
7 Peking University People's Hospital, Beijing, Beijing, China
8 Peking University People's Hospital, Beijing, Beijing, China
9 Peking University People's Hospital, Beijing, Beijing, China
10 Peking University People's Hospital, Beijing, Beijing, China
11 Peking University People's Hospital, Beijing, Beijing, China
12 Peking University People's Hospital, Beijing, Beijing, China
ABSTRACT
Background: Donor specific anti-HLA antibodies (DSA) are associated with graft failure and other adverse hematopoietic stem cell transplantation outcomes. However, the distribution and risk factors of DSA in large, clinically heterogeneous populations of haploidentical allograft candidates remain incompletely defined.
Methods: We analyzed 9,698 consecutive haploidentical allograft candidates enrolled between July 2015 and December 2025. Serum was collected before initiation of haploidentical hematopoietic SCT conditioning, and anti-HLA antibodies were detected using LABScreen mixed and single-antigen bead assays. DSAs were antibodies targeting mismatched donor HLA antigens, and positivity was defined as an MFI ≥ 500. Multivariable binary logistic regression was used to identify risk factors for DSA, with subgroup analyses stratified by age, underlying disease, and sex.
Results: DSA was detected in 9.6% patients (931/9,698). In the total patient cohort, multivariate analysis showed that prior pregnancy (adjusted odds ratio [aOR]=3.792; 95% confidence interval [CI], 3.241-4.436, P<0.001), red blood cell transfusion (aOR=3.509; 95% CI, 2.831-4.351, P<0.001), platelet transfusion (aOR=1.989; 95% CI, 1.636-2.419, P<0.001), and longer disease duration (aOR=1.501; 95% CI, 1.293-1.742, P<0.001) were independently associated with DSA positivity. Regarding the underlying diseases, with AML set as the reference, ALL (aOR=0.676; 95% CI, 0.550-0.831; P<0.001) and other diseases (aOR=0.688; 95% CI, 0.511-0.928; P=0.014) were associated with a lower risk, whereas MDS (aOR=1.308; 95% CI, 1.074-1.592; P=0.008) and AA (aOR=1.534; 95% CI, 1.223-1.925; P<0.001) were associated with a higher risk. For age, compared with children, both adults (aOR=1.686; 95% CI, 1.301-2.183; P<0.001) and elderly patients (aOR=1.747; 95% CI, 1.215-2.512; P=0.003) showed significantly increased likelihood of DSA positivity. Although the risk factors varied across subgroups defined by age, underlying disease, and sex, it is noteworthy that red blood cell transfusion consistently emerged as a significant risk factor in every subgroup.
Conclusions: In this largest cohort study, DSA sensitization was strongly associated with pregnancy, transfusion exposure, disease duration, age, and underlying disease. These findings support risk-adapted DSA monitoring and prompt donor selection in haploidentical transplant candidates.
KEYWORDS: donor specific anti-HLA antibody; haploidentical transplantation; HLA sensitization; pregnancy; transfusion; risk factor
DISCLOSURES
Ning Ma, PhD: No relevant conflicts of interest to declare.